Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Zofia Piotrowska
Relapsed/Refractory Multiple Myeloma: Sequencing CAR T-Cell Therapy and Bispecific Antibodies
Opinion|Videos|July 24, 2026 Author(s)Ajai Chari, MD, Rahul Banerjee, MD, FACP Dr. Ajai Chari and Dr. Rahul Banerjee discuss the increasingly complex treatment sequencing decisions facing clinicians in relapsed/refractory multiple myeloma (RRMM) as the number of highly active immunotherapy options continues to expand.
Establishing the Frontline Monotherapy Backbone in EGFR-Mutant NSCLC
Opinion|Videos|July 22, 2026 (Updated: July 22, 2026) Author(s)Zofia Piotrowska, MD, Heather Wakelee, MD, Samuel Rosner, MD This segment examines single-agent osimertinib as the foundation of first-line EGFR-mutated NSCLC therapy and the benchmark against which combination strategies are measured. This segment examines single-agent osimertinib as the foundation of first-line EGFR-mutated NSCLC therapy and the benchmark against which combination strategies are measured.
Individualizing Frontline Treatment Selection in EGFR-Mutant NSCLC
9th Annual School of Nursing Oncology™ Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A.
Second-Line Treatment Strategies and Emerging Challenges
Dr. Zeidner explores second-line treatment selection complexity arising from frontline agent diversity and failure mechanism variability. Treatment decisions require consideration of initial agent choice (imatinib, second-generation, or asciminib), failure reason (intolerance versus resistance), and resistance mutation profiles when applicable.
Comprehensive Biomarker Testing to Guide Frontline Therapy in EGFR-Mutant NSCLC
This opening segment frames how first-line management of EGFR-mutated advanced non-small cell lung cancer has shifted from a single-agent standard to several guideline-preferred regimens, each carrying distinct efficacy, safety, and administration considerations. The faculty then turn to the molecular testing foundation that must precede any treatment decision, emphasizing complete and timely profiling.
Targeting MET-mediated TKI resistance in EGFR-mutant NSCLC
Get full text access Log in, subscribe or purchase for full access. References 1. Hartmaier, RJ ∙ Markovets, A ∙ Cho, BC ∙ et al. Abstract LB078: tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the phase 2 ORCHARD study Cancer Res. 2022; 82:LB078 2.
Stołeczne władze nie chcą gotówki. Wolą nieruchomości. Zintegrowane Plany Inwestycyjne po warszawsku
Spis treści Debata Architektury: "Umysł, ciało, natura i architektura" Rozwijamy nasz serwis dzięki wyświetlaniu reklam. Blokując reklamy, nie pozwalasz nam tworzyć wartościowych treści. Wyłącz AdBlock i odśwież stronę.
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab | Journal of Clinical Oncology
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions | Journal of Clinical Oncology
Epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins), which comprise approximately 10% of EGFR mutations in non–small-cell lung cancer (NSCLC), are a diverse group of mutations that are structurally distinct from the more common EGFR exon 19 deletions and exon 21 L858R point mutations.
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions | Journal of Clinical Oncology
Epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins), which comprise approximately 10% of EGFR mutations in non–small-cell lung cancer (NSCLC), are a diverse group of mutations that are structurally distinct from the more common EGFR exon 19 deletions and exon 21 L858R point mutations.
Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
OncView™ Podcast: EGFR Exon 20 Insertion as a Therapeutic Target in NSCLC
EGFR Exon 20 Insertion As A Therapeutic Target in Non-small Cell Lung Cancer - Episode 9 In an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.
A retrospective review of the outcomes of patients receiving docetaxel/nintedanib for the treatment of non-small cell lung cancer at the Clatterbridge Cancer Centre, United Kingdom
Recap: Targeted Therapies for EGFR Exon 20 Insertion-Positive NSCLC
Zofia Piotrowska, MD, discusses potential therapies for patients with EGFR exon 20 insertion-positive non–small cell lung cancer. In a recent OncView™ discussion, Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, in Boston, Massachusetts, discussed the identification and targeting of EGFR exon 20 insertion mutations in non–small cell lung cancer (NSCLC).
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms
Highlights • A living biobank of CAFs from NSCLC patients recapitulates clinical CAF heterogeneity • Therapeutic profiling of the NSCLC CAFs reveals three distinctive functional subtypes • Subtype I and II CAFs have high HGF and FGF7 expression and protect cancer cells • Subtype III CAFs associate with better clinical response and immune cell migration Summary Cancer-associated fibroblasts (CAFs) are highly heterogeneous.
Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates
Review Catherine B. Meador, Lecia V. Sequist and Zofia Piotrowska DOI: 10.1158/2159-8290.CD-21-0226 Published September 2021 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below. Abstract Approximately 10% of EGFR-activating mutations occur as in-frame insertion mutations in exon 20 of the EGFR kinase domain (EGFR ins20).
Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
Abstract Background Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has improved survival and central nervous system (CNS) outcomes in patients with non–small cell lung cancer (NSCLC) with activating EGFR mutations. However, little is known about the efficacy and safety of combining osimertinib with chemotherapy. Methods This was a retrospective study performed at 3 institutions.
Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period
Convergence and Technologies David M. McClatchy, Henning Willers, Aaron N. Hata, Zofia Piotrowska, Lecia V. Sequist, Harald Paganetti and Clemens Grassberger DOI: 10.1158/0008-5472.CAN-19-3883 Published November 2020 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Modeling Resistance and Recurrence Patterns of Combined Targeted- Chemoradiotherapy Predicts Benefit of Shorter Induction Period
Research Article David M. McClatchy, Henning Willers, Aaron N. Hata, Zofia Piotrowska, Lecia V. Sequist, Harald Paganetti and Clemens Grassberger DOI: 10.1158/0008-5472.CAN-19-3883 Abstract Optimal integration of molecularly targeted therapies such as tyrosine kinase inhibitors (TKI) with concurrent chemotherapy and radiation (CRT) to improve outcomes in genotype-defined cancers remains a current challenge in clinical settings.
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Abstract Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for patients with advanced EGFR-mutant non -small cell lung cancer (NSCLC). Understanding osimertinib resistance mechanisms and currently available treatment options are essential to selecting optimal second line therapy for patients whose disease progresses during front-line osimertinib.
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Abstract We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6–RET fusion. Although RET fusions have been identified in resistant EGFR-mutant non–small cell lung cancer (NSCLC), their role in acquired resistance to EGFR inhibitors is not well described.
Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz, Justin F. Gainor, Inga T Lennes, Viola W Zhu, Nicolas Marcoux, Mandeep K. Banwait, Subba R Digumarthy, Wenjia Su, Satoshi Yoda, Amanda K. Riley, Varuna Nangia, Jessica J. Lin, Rebecca J. Nagy, Richard B. Lanman, Dora Dias-Santagata, Mari Mino-Kenudson, A.
Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers
The growth of genotype‐directed targeted therapies, such as inhibitors of the epidermal growth factor receptor (EGFR), has revolutionized treatment for some patients with oncogene‐addicted lung cancer. However, as systemic control for these patients has improved, brain metastases remain an important source of morbidity and mortality. Traditional treatment for brain metastases has been radiotherapy, either whole‐brain radiation or stereotactic radiosurgery.
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
AbstractRociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied patients at rociletinib progression to explore resistance mechanisms. Among 12 patients with T790M-positive cancers at rociletinib initiation, six had T790–wild-type rociletinib-resistant biopsies.
Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review
Importance Patients with EGFR-mutant lung cancer benefit from treatment with EGFR inhibitors such as erlotinib, gefitinib, and afatinib, but outcomes are limited by the eventual development of resistance to these agents. Over half of patients acquire a secondary T790M mutation in EGFR at the time of progression and a substantial minority develops resistance through other mechanisms.
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Zofia
Contact Zofia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack